Dr. Peter GK Mathen, M.D.

Claim this profile
Studies Brain Astrocytoma
Studies Glioblastoma
1 reported clinical trial
1 drug studied

Clinical Trials Peter GK Mathen, M.D. is currently running

Image of trial facility.

Radiation Therapy

for Recurrent Brain Tumors

Background: Glioblastoma (GBM) is a cancer of the brain. Current survival rates for people with GBM are poor; survival ranges from 5.2 months to 39 months. Most tumors come back within months or years after treatment, and when they do, they are worse: Overall survival drops to less than 10 months. No standard treatment exists for people whose GBM has returned after radiation therapy. Objective: To find a safe schedule for using radiation to treat GBM tumors that returned after initial radiation treatment. Eligibility: People aged 18 years and older with grade 4 GBM that returned after initial radiation treatment. Design: Participants will be screened. They will have a physical exam with blood tests. A sample of tumor tissue may be collected. Participants will undergo re-irradiation planning: They will wear a plastic mask over their head during imaging scans. These scans will pinpoint the exact location of the tumor. This spot will be the target of the radiation treatments. Participants will undergo radiation treatment 4 times per week. Some people will have this treatment for 3 weeks, some for 2 weeks, and some for 1 week. Blood tests and other exams will be repeated at each visit. Participants will complete questionnaires about their physical and mental health. They will answer these questions before starting radiation treatment; once a week during treatment; and at intervals for up to 3 years after treatment ends. Participants will have follow-up visits 1 month after treatment and then every 2 months for 6 months. Follow-up clinic visits will continue up to 3 years. Follow-ups by phone or email will continue an additional 2 years.
Recruiting1 award Phase 1

More about Peter GK Mathen, M.D.

Clinical Trial Related1 year of experience running clinical trials · Led 1 trial as a Principal Investigator · 1 Active Clinical Trial
Treatments Peter GK Mathen, M.D. has experience with
  • Hypofractionation Trial Of Re-irradiation

Other Doctors you might be interested in

Frequently asked questions

Do I need insurance to participate in a trial?
Almost all clinical trials will cover the cost of the ‘trial drug’ — so no insurance is required for this. For trials where this trial drug is given alongside an already-approved medication, there may be a cost (which your insurance would normally cover).
What does Peter GK Mathen, M.D. specialize in?
Peter GK Mathen, M.D. focuses on Brain Astrocytoma and Glioblastoma. In particular, much of their work with Brain Astrocytoma has involved treating patients, or patients who are undergoing treatment.
Is Peter GK Mathen, M.D. currently recruiting for clinical trials?
Yes, Peter GK Mathen, M.D. is currently recruiting for 1 clinical trial in the USA. If you're interested in participating, you should apply.
Are there any treatments that Peter GK Mathen, M.D. has studied deeply?
Yes, Peter GK Mathen, M.D. has studied treatments such as Hypofractionation Trial of Re-irradiation.
What is the best way to schedule an appointment with Peter GK Mathen, M.D.?
Apply for one of the trials that Peter GK Mathen, M.D. is conducting.
Is there any support for travel costs?
The coverage of travel expenses can vary greatly between different clinical trials. Please see more financial detail in the trials you’re interested to apply.